Bonopus Bio

Bonopus Bio is a biotechnology company focused on the discovery and development of novel small molecule therapeutics through targeted protein degradation (TPD). The company leverages its proprietary platform to design molecular glues and PROTACs aimed at degrading disease-causing proteins that are traditionally difficult to target with conventional inhibitors. Bonopus Bio primarily focuses on high-impact targets within oncology and immunology to address significant unmet medical needs. Headquartered in Shanghai with additional operations in the United States, the company is supported by leading venture capital firms to advance its early-stage pipeline toward clinical validation.